MCID: SFT003
MIFTS: 58

Soft Tissue Sarcoma

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Soft Tissue Sarcoma

MalaCards integrated aliases for Soft Tissue Sarcoma:

Name: Soft Tissue Sarcoma 49 28 40
Sarcoma 69

Classifications:



External Ids:

UMLS 69 C1261473

Summaries for Soft Tissue Sarcoma

NIH Rare Diseases : 49 Soft tissuesarcoma is a form of cancer that occurs due to abnormal and uncontrolled cell growth of the "soft tissues" of the body. These tissues connect, support and surround other body parts and may include muscle, fat, blood vessels, lymph vessels, nerves, tendons and the lining of joints. Many people with early soft tissue sarcoma have no signs or symptoms of the condition. When present, symptoms depend on the location and size of the tumor but may include a palpable lump under the skin, pain, or difficulty breathing. Most cases occur sporadically in people with little to no family history of the condition. People who have previously received radiation therapy and those with certain inherited disorders (such as Gorlin syndrome, Gardner syndrome, Li-Fraumeni syndrome, Tuberous sclerosis, neurofibromatosis type 1, and Werner syndrome) have an increased risk of developing a soft tissue sarcoma. The best treatment options depend on many factors but may include surgery, chemotherapy, and radiation therapy. Last updated: 10/17/2016

MalaCards based summary : Soft Tissue Sarcoma, also known as sarcoma, is related to myxoid liposarcoma and rhabdomyosarcoma. An important gene associated with Soft Tissue Sarcoma is MDM2 (MDM2 Proto-Oncogene), and among its related pathways/superpathways are Akt Signaling and Cytokine Signaling in Immune system. The drugs Doxorubicin and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and t cells, and related phenotypes are endocrine/exocrine gland and cardiovascular system

MedlinePlus : 40 Your soft tissues connect, support, or surround other tissues. Examples include your muscles, tendons, fat, and blood vessels. Soft tissue sarcoma is a cancer of these soft tissues. There are many kinds, based on the type of tissue they started in. They may cause a lump or swelling in the soft tissue. Sometimes they spread and can press on nerves and organs, causing problems such as pain or trouble breathing. No one knows exactly what causes these cancers. They are not common, but you have a higher risk if you have been exposed to certain chemicals, have had radiation therapy, or have certain genetic diseases. Doctors diagnose soft tissue sarcomas with a biopsy. Treatments include surgery to remove the tumor, radiation therapy, chemotherapy, or a combination. NIH: National Cancer Institute

Wikipedia : 72 A soft-tissue sarcoma is a form of sarcoma that develops in connective tissue, though the term is... more...

Related Diseases for Soft Tissue Sarcoma

Diseases related to Soft Tissue Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 231)
# Related Disease Score Top Affiliating Genes
1 myxoid liposarcoma 32.4 EWSR1 MDM2 TP53
2 rhabdomyosarcoma 32.2 EWSR1 FOXO1 MDM2 TP53
3 gastrointestinal stromal tumor 31.9 MKI67 TP53 VEGFA
4 muscle cancer 31.6 EWSR1 FOXO1 MDM2 TP53
5 li-fraumeni syndrome 31.5 BCL2 EGFR MDM2 TP53
6 histiocytoma 30.6 EWSR1 MDM2 TP53
7 liposarcoma 30.5 EWSR1 MDM2 TP53
8 malignant peripheral nerve sheath tumor 30.1 EGFR MDM2 TP53
9 glioblastoma 29.2 EGFR MDM2 TP53 VEGFA
10 myeloma, multiple 29.1 ABCB1 TP53 VEGFA
11 renal cell carcinoma, nonpapillary 28.7 ABCB1 EGFR IFNG VEGFA
12 leukemia, acute myeloid 28.1 ABCB1 IFNG MDM2 TERT TNF TP53
13 ewing sarcoma 28.0 EGFR EWSR1 FOXO1 IFNG MDM2 TNF
14 ovarian cancer 27.1 ABCB1 BCL2 EGFR MDM2 TERT TNF
15 lung cancer 27.0 ABCB1 BCL2 EGFR MDM2 TERT TP53
16 breast cancer 26.9 ABCB1 BCL2 EGFR FOXO1 MDM2 MKI67
17 colorectal cancer 25.9 ABCB1 BCL2 EGFR IFNG MDM2 MKI67
18 soft tissue sarcoma childhood 12.2
19 alveolar soft part sarcoma 12.0
20 sarcoma, synovial 11.6
21 dermatofibrosarcoma protuberans 11.5
22 epithelioid sarcoma 11.5
23 hemangiopericytoma, malignant 11.4
24 rhabdomyosarcoma 2 11.3
25 sarcoma 11.2
26 undifferentiated pleomorphic sarcoma 11.1
27 connective tissue disease 11.0
28 synovium cancer 11.0
29 rhabdomyosarcoma, embryonal, 1 11.0
30 malignant fibroxanthoma 11.0
31 heart malignant hemangiopericytoma 11.0
32 rhabdomyosarcoma, embryonal, 2 11.0
33 follicular dendritic cell sarcoma 11.0
34 ring chromosome 7 10.5 MDM2 TP53
35 conventional central osteosarcoma 10.5 EWSR1 MDM2
36 tetraploidy 10.5 LATS1 TP53
37 spindle cell lipoma 10.4 FOXO1 MDM2
38 sclerosing liposarcoma 10.4 MDM2 TP53
39 lip cancer 10.4 MDM2 TP53
40 blood group, i system 10.4
41 spitz nevus 10.4 MKI67 TP53
42 anal squamous cell carcinoma 10.4 MDM2 TP53
43 staphylococcal toxic shock syndrome 10.4 IFNG TNF
44 infiltrating angiolipoma 10.3 MDM2 VEGFA
45 autoimmune myocarditis 10.3 IFNG TNF
46 malignant mesenchymoma 10.3 EWSR1 MDM2 TP53
47 actinic cheilitis 10.3 MDM2 TNF TP53
48 critical limb ischemia 10.3 TNF VEGFA
49 chronic beryllium disease 10.3 IFNG TNF
50 trichosporonosis 10.3 IFNG TNF

Graphical network of the top 20 diseases related to Soft Tissue Sarcoma:



Diseases related to Soft Tissue Sarcoma

Symptoms & Phenotypes for Soft Tissue Sarcoma

MGI Mouse Phenotypes related to Soft Tissue Sarcoma:

43 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.32 ABCB1 EGFR BCL2 FOXO1 LATS1 IFNG
2 cardiovascular system MP:0005385 10.31 ABCB1 EGFR BCL2 FOXO1 LATS1 IFNG
3 growth/size/body region MP:0005378 10.31 ABCB1 EGFR BCL2 FOXO1 LATS1 IFNG
4 cellular MP:0005384 10.3 EGFR BCL2 IFNG FOXO1 LATS1 TERT
5 digestive/alimentary MP:0005381 10.29 ABCB1 EGFR BCL2 FOXO1 IFNG MDM2
6 homeostasis/metabolism MP:0005376 10.29 ABCB1 EGFR BCL2 IFNG FOXO1 LATS1
7 hematopoietic system MP:0005397 10.26 ABCB1 EGFR BCL2 IFNG FOXO1 MDM2
8 immune system MP:0005387 10.24 ABCB1 EGFR BCL2 IFNG FOXO1 MDM2
9 mortality/aging MP:0010768 10.22 BCL2 ABCB1 EGFR IFNG FOXO1 LATS1
10 craniofacial MP:0005382 10.2 EGFR BCL2 FOXO1 IFNG MDM2 TNF
11 embryo MP:0005380 10.19 EGFR BCL2 IFNG FOXO1 MDM2 TNF
12 integument MP:0010771 10.18 EGFR BCL2 FOXO1 LATS1 IFNG MDM2
13 liver/biliary system MP:0005370 10.15 ABCB1 EGFR FOXO1 LATS1 IFNG MDM2
14 neoplasm MP:0002006 10.13 EGFR BCL2 FOXO1 LATS1 IFNG MDM2
15 nervous system MP:0003631 10.1 ABCB1 EGFR BCL2 IFNG LATS1 MDM2
16 no phenotypic analysis MP:0003012 10.07 ABCB1 EGFR FOXO1 LATS1 IFNG MDM2
17 muscle MP:0005369 10.06 EGFR BCL2 FOXO1 IFNG MDM2 TNF
18 limbs/digits/tail MP:0005371 9.99 EGFR FOXO1 MDM2 TNF VEGFA TP53
19 normal MP:0002873 9.97 EGFR FOXO1 LATS1 IFNG MDM2 MKI67
20 reproductive system MP:0005389 9.9 ABCB1 EGFR BCL2 FOXO1 LATS1 IFNG
21 renal/urinary system MP:0005367 9.73 BCL2 EGFR IFNG MDM2 VEGFA TP53
22 respiratory system MP:0005388 9.43 EGFR IFNG TERT TNF VEGFA TP53
23 skeleton MP:0005390 9.23 EGFR IFNG FOXO1 TERT MDM2 TNF

Drugs & Therapeutics for Soft Tissue Sarcoma

Drugs for Soft Tissue Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 598)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
3
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 155213-67-5 392622
4
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
6
Bleomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
7
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
8
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
9
Heparin Approved, Investigational Phase 4,Phase 1 9005-49-6 46507594 772
10
Aspirin Approved, Vet_approved Phase 4,Phase 2 50-78-2 2244
11
Lopinavir Approved Phase 4,Phase 2,Phase 3 192725-17-0 92727
12
Nevirapine Approved Phase 4,Phase 3 129618-40-2 4463
13
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3 134678-17-4 60825
14
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
15
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 1 154361-50-9 60953
16
Emtricitabine Approved, Investigational Phase 4,Phase 3 143491-57-0 60877
17
Dalteparin Approved Phase 4,Phase 1 9005-49-6
18
Ethiodized oil Approved, Investigational Phase 4 8008-53-5
19
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
20 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
21 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
23 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
25 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
26 Vaccines Phase 4,Phase 1,Phase 2
27 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
28 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
29 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Antibodies, Monoclonal Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
33 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Anti-HIV Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Immunoglobulins Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
37 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
39 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1
41 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
42 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
43 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
44 Antibodies Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
45 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
47
Tenofovir Phase 4,Phase 3 147127-20-6 464205
48 calcium heparin Phase 4,Phase 1
49 Lithium carbonate Phase 4 554-13-2
50 Fibrinolytic Agents Phase 4,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 1704)

# Name Status NCT ID Phase Drugs
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
2 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
3 HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
4 Anti-Retrovirals for Kaposi's Sarcoma Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
5 OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum. Completed NCT00577031 Phase 4 bevacizumab [Avastin];Oxaliplatin;Xeloda
6 Physical Characteristics of Retrieved Massive Allografts Completed NCT00160758 Phase 4
7 HLA Sensitization Following Major Cortical Allograft Bone Procedures Completed NCT00160719 Phase 4
8 Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection Recruiting NCT03144206 Phase 4 Hyperbaric oxygen
9 Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer Recruiting NCT02301962 Phase 4 Panitumumab
10 Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma Recruiting NCT01669369 Phase 4 Lithium Carbonate;Placebo
11 Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. Recruiting NCT02625389 Phase 4 Lipiodol® Ultra Fluid with surgical glues
12 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
13 Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology Not yet recruiting NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
14 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
15 The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
16 An Adequate Cost Effective Follow Up Protocol For Bone & Soft Tissue Sarcomas - A Prospective Randomized Trial Unknown status NCT00384735 Phase 3
17 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
18 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
19 A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
20 Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
21 TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
22 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
23 Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor Unknown status NCT00685828 Phase 3 imatinib mesylate
24 Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor Unknown status NCT00103168 Phase 3 imatinib mesylate
25 A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma Unknown status NCT02099396 Phase 2, Phase 3 Docetaxel+lobaplatin;Gemcitabine+lobaplatin
26 Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma Unknown status NCT00691236 Phase 2, Phase 3 Zoledronic acid;Standard chemotherapy
27 Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma Unknown status NCT01091883 Phase 3
28 A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Completed NCT01440088 Phase 3 TH-302 in Combination with Doxorubicin;Doxorubicin
29 Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma Completed NCT00142571 Phase 3 Gemcitabine;Docetaxel
30 Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Completed NCT02049905 Phase 3 Aldoxorubicin;Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
31 Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma Completed NCT01168791 Phase 3 doxorubicin in combination with palifosfamide-tris;doxorubicin in combination with placebo
32 Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3 PAZOPANIB;Placebo
33 Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma Completed NCT01327885 Phase 3 Eribulin mesylate 1.4 mg/m^2 intravenous;Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
34 A Prospective Randomized Trial of Pre-Operative IMRT+Surgery Versus Surgery Alone For Primary Retroperitoneal Sarcoma Completed NCT00131898 Phase 3
35 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
36 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
37 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
38 Observation Versus Post-surgery Radiotherapy After Complete Exeresis in Soft Tissues Members Sarcoma Completed NCT00870701 Phase 3
39 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
40 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
41 Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002985 Phase 3 daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride
42 A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma Completed NCT00001300 Phase 3 doxorubicin;ifosfamide;mesna
43 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
44 An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) Completed NCT00796120 Phase 3 Trabectedin;Doxorubicin;Ifosfamide
45 A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies Completed NCT00699517 Phase 3 OMBRABULIN (AVE8062);Placebo
46 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
47 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
48 Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) Completed NCT00538239 Phase 3 ridaforolimus;Placebo
49 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
50 A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe Completed NCT00834457 Phase 2, Phase 3 abacavir/3TC/zidovudine;abacavir /3TC plus ritonavir boosted lopinavir

Search NIH Clinical Center for Soft Tissue Sarcoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Soft Tissue Sarcoma

Genetic tests related to Soft Tissue Sarcoma:

# Genetic test Affiliating Genes
1 Soft Tissue Sarcoma 28

Anatomical Context for Soft Tissue Sarcoma

MalaCards organs/tissues related to Soft Tissue Sarcoma:

38
Bone, Lung, T Cells, Uterus, Testes, Brain, Kidney

Publications for Soft Tissue Sarcoma

Articles related to Soft Tissue Sarcoma:

(show top 50) (show all 1042)
# Title Authors Year
1
Near-infrared intraoperative imaging during resection of an anterior mediastinal soft tissue sarcoma. ( 29387401 )
2018
2
Characterizing the potency and impact of carbon ion therapy in a primary mouse model of soft tissue sarcoma. ( 29437879 )
2018
3
Validation of a hypoxia related gene signature in multiple soft tissue sarcoma cohorts. ( 29423096 )
2018
4
Olaratumab in soft tissue sarcoma - Current status and future perspectives. ( 29413687 )
2018
5
Correction: Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. ( 29339354 )
2018
6
Radiation-related soft tissue sarcoma in a veterinary technician. ( 29398573 )
2018
7
Does an Algorithmic Approach to Using Brachytherapy and External Beam Radiation Result in Good Function, Local Control Rates, and Low Morbidity in Patients With Extremity Soft Tissue Sarcoma? ( 29443850 )
2018
8
Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients. ( 29384032 )
2018
9
Advances in the treatment of soft tissue sarcoma: focus on eribulin. ( 29440930 )
2018
10
Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). ( 29383713 )
2018
11
Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. ( 29450452 )
2018
12
Analysis of Margin Classification Systems for Assessing the Risk of Local Recurrence After Soft Tissue Sarcoma Resection. ( 29346043 )
2018
13
Long-term outcomes of patients with soft tissue sarcoma of the chest wall: Analysis of the prognostic significance of microscopic margins. ( 29434923 )
2018
14
Eribulin therapy for the treatment of patients with advanced soft tissue sarcoma. ( 29411654 )
2018
15
Factors Associated With Acute and Chronic Wound Complications in Patients With Soft Tissue Sarcoma With Long-term Follow-up. ( 29315173 )
2018
16
The AJCC 8th Edition Staging System for Soft Tissue Sarcoma of the Extremities or Trunk: A Cohort Study of the SEER Database. ( 29439175 )
2018
17
CORR InsightsAr: Does an Algorithmic Approach to Using Brachytherapy and External Beam Radiation Result in Good Function, Local Control Rates, and Low Morbidity in Patients With Extremity Soft Tissue Sarcoma? ( 29443851 )
2018
18
AZGP1 inhibits soft tissue sarcoma cells invasion and migration. ( 29357838 )
2018
19
miR-429 inhibits metastasis by targeting KIAA0101 in Soft Tissue Sarcoma. ( 28432002 )
2017
20
Surgical considerations when reporting MRI studies of soft tissue sarcoma of the limbs. ( 28884363 )
2017
21
Alveolar soft part sarcoma in children and adolescents: The European Paediatric Soft Tissue Sarcoma study group prospective trial (EpSSG NRSTS 2005). ( 29286582 )
2017
22
Treatment of soft tissue sarcoma: a focus on earlier stages. ( 27918202 )
2017
23
Benefit of Adjuvant Radiotherapy for Local Control, Distant Metastasis, and Survival Outcomes in Patients with Localized Soft Tissue Sarcoma: Comparative Effectiveness Analysis of an Observational Cohort Study. ( 28895087 )
2017
24
MicroRNAs in Different Histologies of Soft Tissue Sarcoma: A Comprehensive Review. ( 28895916 )
2017
25
Myositis ossificans in elbow mimicking soft tissue sarcoma: Similar clinical and radiological findings. ( 28641932 )
2017
26
Prediction of muscle strength and postoperative function after knee flexor muscle resection for soft tissue sarcoma of the lower limbs. ( 28827055 )
2017
27
Optimal post-operative radiation after soft-tissue sarcoma resection is achieved in less than two thirds of cases. ( 28842782 )
2017
28
Appendix 3: Soft tissue sarcoma: MCBS eUpdate published online 5 May 2017(www.esmo.org/Guidelines/Sarcoma-and-GIST). ( 28881924 )
2017
29
Aldoxorubicin for the treatment of soft tissue sarcoma. ( 28846045 )
2017
30
Curcumin and Viscum album Extract Decrease Proliferation and Cell Viability of Soft-Tissue Sarcoma Cells: An In Vitro Analysis of Eight Cell Lines Using Real-Time Monitoring and Colorimetric Assays. ( 28045549 )
2017
31
Salvage Therapy in Advanced Adult Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis of Randomized Trials. ( 28835514 )
2017
32
PD-L1 Expression Is Associated with FOXP3+ Regulatory T-Cell Infiltration of Soft Tissue Sarcoma and Poor Patient Prognosis. ( 28819402 )
2017
33
Randomized Controlled Trials in Soft Tissue Sarcoma: We Are Getting There! ( 28923218 )
2017
34
Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas. ( 28988501 )
2017
35
Olaratumab for the treatment of advanced soft tissue sarcoma. ( 28862476 )
2017
36
External Beam Radiation Therapy for Resectable Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis. ( 28895107 )
2017
37
GeDDiS: insight into frontline therapy in soft tissue sarcoma. ( 28882535 )
2017
38
Cost-Effectiveness Analysis of Preoperative Versus Postoperative Radiation Therapy in Extremity Soft Tissue Sarcoma. ( 28068242 )
2017
39
Hypoxia-inducible factor 1I+ predicts recurrence in high-grade soft tissue sarcoma of extremities and trunk wall. ( 28404817 )
2017
40
The importance of treating by histological subtype in advanced soft tissue sarcoma. ( 27918201 )
2017
41
Clinicopathological and prognostic value of transforming acidic coiled-coil-containing protein 3 (TACC3) expression in soft tissue sarcomas. ( 29135996 )
2017
42
Ovary-Sparing Radiation Planning Techniques Can Achieve Ovarian Dose Reduction for Soft Tissue Sarcoma of the Buttock and Thigh. ( 29311758 )
2017
43
Antia89proliferative activity of epigallocatechina893a89gallate and silibinin on soft tissue sarcoma cells. ( 27909727 )
2017
44
Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal. ( 28914440 )
2017
45
Dramatic Reduction in Tumor Size During 5 Months of Pazopanib Therapy in Combination With Ifosfamide, Carboplatin, and Etoposide in an Early Infant With Progressive Soft Tissue Sarcoma. ( 28067691 )
2017
46
A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma. ( 28926423 )
2017
47
Comparison of novel multi-level Otsu (MO-PET) and conventional PET segmentation methods for measuring FDG metabolic tumor volume in patients with soft tissue sarcoma. ( 28921170 )
2017
48
45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. ( 28548706 )
2017
49
Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STS) Protocol 0303. ( 29043525 )
2017
50
Pitfalls in soft tissue sarcoma imaging: chronic expanding hematomas. ( 28887645 )
2017

Variations for Soft Tissue Sarcoma

Cosmic variations for Soft Tissue Sarcoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM575 NRAS soft tissue,skin,sarcoma,NS c.38G>C p.G13A 13

Expression for Soft Tissue Sarcoma

Search GEO for disease gene expression data for Soft Tissue Sarcoma.

Pathways for Soft Tissue Sarcoma

Pathways related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.35 BCL2 EGFR FOXO1 MDM2 TNF TP53
2
Show member pathways
13.28 BCL2 EGFR FOXO1 IFNG TNF TP53
3
Show member pathways
13.15 BCL2 EGFR FOXO1 IFNG TNF TP53
4
Show member pathways
12.98 BCL2 EGFR FOXO1 MDM2 TP53 VEGFA
5
Show member pathways
12.72 ABCB1 BCL2 EGFR TERT TP53
6
Show member pathways
12.68 BCL2 EGFR FOXO1 MDM2 TERT TNF
7
Show member pathways
12.61 EGFR IFNG TNF TP53
8
Show member pathways
12.52 BCL2 TNF TP53 VEGFA
9
Show member pathways
12.51 BCL2 EGFR MDM2 TP53 VEGFA
10 12.47 LATS1 MDM2 MKI67 TP53
11
Show member pathways
12.44 BCL2 EGFR FOXO1 IFNG TNF TP53
12
Show member pathways
12.4 BCL2 EGFR MDM2 TP53
13
Show member pathways
12.4 EGFR FOXO1 MDM2 TP53 VEGFA
14 12.32 ABCB1 BCL2 EGFR MDM2 TP53 VEGFA
15 12.28 BCL2 EGFR FOXO1 IFNG MDM2 TERT
16 12.27 BCL2 IFNG MDM2 TP53
17 12.22 EWSR1 FOXO1 MDM2 TP53
18 12.18 EGFR MDM2 TNF TP53 VEGFA
19
Show member pathways
12.15 BCL2 EGFR FOXO1 MDM2 TP53
20
Show member pathways
12.1 EGFR MDM2 TP53 VEGFA
21 12.07 EGFR IFNG TNF TP53 VEGFA
22
Show member pathways
12.04 EGFR FOXO1 MDM2
23 12.02 BCL2 MDM2 TP53
24 12.02 BCL2 MDM2 TP53 VEGFA
25 12.02 BCL2 EGFR MDM2 TP53
26 12.01 EGFR TNF TP53
27 11.96 BCL2 TNF TP53
28 11.96 EGFR IFNG TNF TP53
29 11.95 FOXO1 MDM2 TP53
30 11.95 BCL2 MDM2 TP53
31
Show member pathways
11.94 BCL2 TNF TP53
32 11.94 BCL2 IFNG TNF TP53 VEGFA
33 11.92 EGFR FOXO1 MDM2 TP53
34 11.87 BCL2 IFNG MDM2 TP53
35 11.83 EGFR FOXO1 MDM2
36 11.83 BCL2 EGFR IFNG VEGFA
37 11.82 IFNG TNF VEGFA
38 11.82 BCL2 EGFR FOXO1 MDM2 TP53 VEGFA
39 11.81 BCL2 FOXO1 TNF VEGFA
40 11.78 BCL2 FOXO1 TNF TP53 VEGFA
41 11.77 IFNG MDM2 TP53
42 11.72 BCL2 MDM2 TP53
43 11.67 EGFR IFNG TERT
44 11.66 ABCB1 TERT VEGFA
45 11.66 EGFR MDM2 TP53 VEGFA
46
Show member pathways
11.64 IFNG TNF VEGFA
47 11.57 FOXO1 MDM2 TP53
48 11.57 MDM2 TP53 VEGFA
49 11.5 EGFR TNF VEGFA
50 11.5 EGFR IFNG TNF

GO Terms for Soft Tissue Sarcoma

Biological processes related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription, DNA-templated GO:0045892 9.99 FOXO1 IFNG MDM2 TNF TP53
2 positive regulation of cell proliferation GO:0008284 9.98 BCL2 EGFR IFNG MDM2 VEGFA
3 cell proliferation GO:0008283 9.95 BCL2 EGFR MKI67 TP53
4 positive regulation of apoptotic process GO:0043065 9.93 FOXO1 LATS1 TNF TP53
5 response to drug GO:0042493 9.91 ABCB1 BCL2 MDM2 TP53
6 positive regulation of gene expression GO:0010628 9.91 IFNG MDM2 TNF TP53 VEGFA
7 response to oxidative stress GO:0006979 9.83 BCL2 EGFR TP53
8 positive regulation of protein phosphorylation GO:0001934 9.83 EGFR IFNG TNF VEGFA
9 positive regulation of MAP kinase activity GO:0043406 9.75 EGFR TNF VEGFA
10 humoral immune response GO:0006959 9.74 BCL2 IFNG TNF
11 protein kinase B signaling GO:0043491 9.73 FOXO1 MDM2 TNF
12 positive regulation of nitric oxide biosynthetic process GO:0045429 9.72 EGFR IFNG TNF
13 negative regulation of apoptotic process GO:0043066 9.7 BCL2 EGFR FOXO1 MDM2 TERT TP53
14 positive regulation of osteoclast differentiation GO:0045672 9.67 IFNG TNF
15 response to iron ion GO:0010039 9.66 BCL2 MDM2
16 positive regulation of protein export from nucleus GO:0046827 9.65 MDM2 TP53
17 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.65 IFNG TNF
18 negative regulation of gene expression GO:0010629 9.65 IFNG MDM2 TERT TNF VEGFA
19 digestive tract morphogenesis GO:0048546 9.64 BCL2 EGFR
20 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.64 MDM2 TERT
21 positive regulation of leukocyte migration GO:0002687 9.63 TP53 VEGFA
22 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.63 BCL2 TERT TNF
23 growth GO:0040007 9.62 BCL2 VEGFA
24 regulation of mitochondrial membrane permeability GO:0046902 9.62 BCL2 TP53
25 replicative senescence GO:0090399 9.61 TERT TP53
26 negative regulation of mitotic cell cycle GO:0045930 9.61 BCL2 EGFR TNF
27 response to UV-B GO:0010224 9.6 BCL2 TP53
28 positive regulation of protein complex assembly GO:0031334 9.54 IFNG TNF VEGFA
29 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.5 MDM2 TERT TNF
30 cellular response to actinomycin D GO:0072717 9.49 MDM2 TP53
31 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.48 IFNG TNF
32 positive regulation of vitamin D biosynthetic process GO:0060557 9.4 IFNG TNF
33 cellular response to hypoxia GO:0071456 9.35 BCL2 MDM2 TERT TP53 VEGFA
34 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.02 BCL2 EGFR LATS1 TNF VEGFA
35 negative regulation of transcription by RNA polymerase II GO:0000122 10.01 FOXO1 IFNG MDM2 TNF TP53 VEGFA

Molecular functions related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.58 BCL2 TNF TP53
2 protein N-terminus binding GO:0047485 9.54 MDM2 TERT TP53
3 protein phosphatase binding GO:0019903 9.5 BCL2 EGFR TP53
4 transcription coactivator binding GO:0001223 9.43 FOXO1 TERT
5 ubiquitin protein ligase binding GO:0031625 9.35 BCL2 EGFR FOXO1 MDM2 TP53
6 protein phosphatase 2A binding GO:0051721 9.33 BCL2 FOXO1 TP53
7 identical protein binding GO:0042802 9.23 BCL2 EGFR EWSR1 MDM2 TERT TNF
8 protein binding GO:0005515 10.07 ABCB1 BCL2 EGFR EWSR1 FOXO1 IFNG

Sources for Soft Tissue Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....